compounds that enhance autophagy have the potential to treat a wide range of neurodegenerative disease.
- MPL mechanism of action enhances autophagy.
- next week, we will know if this enhanced autophagy treats at least one neurodegenerative disease
- if yes, then the Professor says that it has the potential to treat a range of other neurodegenerative diseases.
That is, success next week, and value goes up by more that % success attributed to becoming SoC for MND/ALS ( 50% ? ).
You need to start throwing a % chance of success against other indications ( Alzheimer's Disease, Parkinson's etc. ), maybe 5%.
And that gets built into any offer for PAA.
Ann: PharmAust Forms World-Class Scientific Advisory Board, page-11
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
-0.020(8.89%) |
Mkt cap ! $81.16M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 21.0¢ | 19.5¢ | $331.9K | 1.617M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 440882 | 20.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 12736 | 3 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| PAA (ASX) Chart |